ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2102

Is This Prosthetic Joint Infected or Flaring?

Susan Goodman, Insa Mannstadt, Kathleen Tam, Alejandro Kochen, Lorien Shakib, Peter Sculco, Mark Figgie, Alberto Carli, Andy Miller, Linda Russell, Allina Nocon and Laura Donlin, Hospital for Special Surgery, New York, NY

Meeting: ACR Convergence 2023

Keywords: Arthroplasty, autoimmune diseases, Diagnostic criteria, Infection, Prosthetic Joint

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Diagnosis of a periprosthetic joint infection (PJI) in a patient with inflammatory arthritis (IA) is challenging, as features of IA flares can mimic an infection. We aimed to identify the optimal tests to diagnose a PJI accurately and efficiently in patients with IA.

Methods: We included participants in three patient groups: 1) IA patients with a flaring native joint, 2) IA patients with a prosthetic joint undergoing aseptic revision, and 3) patients with PJI regardless of IA. Demographic characteristics were compared across the three groups. Blood and synovial fluid markers were compared across groups to assess the sensitivity and specificity in diagnosing PJI versus IA flares.

Results: This study included 52 participants, mostly female (60%), and 40% had rheumatoid arthritis. Among the three groups, the confirmed PJI patients were older (p=0.03), while no significant statistical differences were observed in the remaining demographic variables. Synovial fluid and blood markers were significantly different between groups. PJI cases had the highest average C-Reactive Protein (CRP) and there was a significant difference between the groups (PJI: 82 mg/dl, IA flares: 29 mg/dl, aseptic revisions:10 mg/dl, p< 0.05) (Table 2). Similarly, the percent of synovial fluid polymorphonuclear neutrophils (PMNs) was highest in PJI cases and significantly differed between groups (PJI: 88.9%, IA flares: 54%, aseptic revisions: 17%, p< 0.01). Among PJI cases, alpha-defensin was positive in 93%. However, positive alpha-defensin was also observed in 20% of flares and 6% of aseptic revisions, with a significant difference (p< 0.01). There was no significant difference in procalcitonin and IL-6 levels across groups. Synovial white blood cells (WBC) exceeding 3,000 cells/µL, positive alpha-defensin, CRP levels exceeding 3 mg/dl, and PMNs exceeding 80% were highly sensitivity but less specific in diagnosing PJI (Table 3). Synovial WBC counts exceeding 3,000 cells/µL, alpha-defensin positivity, CRP level exceeding 3 mg/dl, and PMNs exceeding 80% were highly sensitive yet less specific for PJI diagnosis. For example, while synovial WBC counts exceeding 3,000 cells/µL and positive alpha-defensin had 100% sensitivity for identifying PJI, their specificity was poor with 50% of IA native joint flares and 79% of aseptic revisions scoring positive for an infection, respectively. The relatively poor specificity of synovial WBC and alpha-defensin indicate that that there is a higher likelihood of these tests incorrectly detecting PJI in cases where it is not present. Positive tests for alpha-defensin or synovial fluid PMNs exceeding 80% increased the likelihood of diagnosing PJI by 5 and 6 times, respectively. However, in cases without PJI, a negative result for PMNs exceeding 80% only marginally increased the likelihood of accurately ruling out diagnosis by 1 time. IL-6, procalcitonin, and D-Dimer demonstrated high sensitivity and specificity, while ESR and CRP had 80% sensitivity but had significantly lower specificity.

Conclusion: Diagnosing PJI in patients with inflammatory arthritis remains challenging. Current efforts are examining whether next-generation sequencing may prove more effective than common clinical tests.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Goodman: NIH, 5, Novartis, 5; I. Mannstadt: None; K. Tam: None; A. Kochen: None; L. Shakib: None; P. Sculco: DePuy Synthes, 2, EOS Imaging, 2, Intellijoint Surgical, 2, 5, Lima Corporate, 2, Zimmer Biomet, 2, 5; M. Figgie: hs2, 8, joint effort aso, 8, lima, 2, 9, wishbone medical, 2, 4, 8, 9, 10; A. Carli: None; A. Miller: None; L. Russell: None; A. Nocon: None; L. Donlin: Bristol-Myers Squibb(BMS), 2, Stryker, 2.

To cite this abstract in AMA style:

Goodman S, Mannstadt I, Tam K, Kochen A, Shakib L, Sculco P, Figgie M, Carli A, Miller A, Russell L, Nocon A, Donlin L. Is This Prosthetic Joint Infected or Flaring? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/is-this-prosthetic-joint-infected-or-flaring/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-this-prosthetic-joint-infected-or-flaring/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology